Latest news with #PiersIngram
Associated Press
6 days ago
- Business
- Associated Press
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Hummingbird Bioscience Media Contact: Crystal Ho [email protected] [email protected] +65 6979 5580 Hummingbird Bioscience Investor Contact: [email protected]
Business Upturn
7 days ago
- Business
- Business Upturn
Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics
Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience's anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron Therapeutics Percheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a biotherapeutics company discovering and developing transformative medicines for hard-to-treat diseases, today announced that it has granted Percheron Therapeutics Limited (ASX: PER) an exclusive worldwide license to develop, manufacture, and commercialize HMBD-002 in all territories and indications. Under the terms of the agreement, Hummingbird Bioscience will be eligible to receive up to USD 290 million in upfront and milestone payments, plus royalties on net sales. HMBD-002 is a monoclonal antibody therapy targeting VISTA, a novel checkpoint involved in the body's immune response to cancer. HMBD-002 has successfully completed a phase I clinical trial in the United States, under an Investigational New Drug application with the US Food and Drug Administration, which showed the drug to be pharmacologically active and generally safe and well-tolerated. Percheron Therapeutics aims to continue clinical development of HMBD-002 in CY2026. 'Given the potential benefits of VISTA blockade in multiple cancers that have strong evidence of VISTA-mediated immune suppression, HMBD-002 is a scientifically compelling asset for both monotherapy and combination approaches. We are pleased to have Percheron Therapeutics continue the clinical development of HMBD-002,' said Piers Ingram, PhD, co-founder and Chief Executive Officer of Hummingbird Bioscience. 'We have confidence in the potential clinical benefit of HMBD-002 and in Percheron's ability to successfully progress HMBD-002 through the clinic.' 'Hummingbird Bioscience lies at the cutting edge of novel drug design, and we are delighted to partner with them to take forward this very promising drug candidate,' said Dr. James Garner, Chief Executive Officer of Percheron Therapeutics. 'We selected HMBD-002 out of more than a hundred individual drug candidates from more than seventy companies, and we very much hope that this exciting program can bring meaningful benefit to patients confronting the enormous challenge of a cancer diagnosis.' About HMBD-002 HMBD-002 is a novel anti-VISTA neutralizing antibody, and the only IgG4 isotype anti-VISTA antibody currently in development. HMBD-002 was engineered to bind to VISTA at a specific site that is predicted to be essential for ligand binding and function, thus inhibiting VISTA and neutralizing its immunosuppressive activity without depleting VISTA-expressing cells that play many important roles in the immune system. About Hummingbird Bioscience Hummingbird Bioscience is a biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube. About Percheron Therapeutics Limited Percheron Therapeutics Limited [ASX: PER | US OTC: PERCF] is a publicly listed biotechnology company focused on the development and commercialization of novel therapies for oncology and rare diseases. The company's lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer, which has shown the drug to be generally safe and well-tolerated. For more information, please contact [email protected]. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
03-03-2025
- Business
- Yahoo
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Investment will contribute to achieve clinical proof-of-concept for Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech). The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy. Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms. Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member. Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: 'We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. ' Rachel Mears, Parner at Jeito Capital added: 'Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. ' Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: 'We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.' About Jeito CapitalJeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United more information, please visit or follow us on LinkedIn or X. About Callio Therapeutics Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit and follow Callio Therapeutics on LinkedIn. Contacts:Jeito Capital Rafaèle Tordjman, Founder & CEOJessica Fadel, EATel: +33 6 33 44 25 47 MaiorStéphanie Elbaz – Tel: +33 6 46 05 08 07 ICR HealthcareMary-Jane Elliott / Davide Salvi / Kris LamJeito@ +44 (0) 20 3709 5700 1 EUR/USD exchange rate: 1 EUR = 1.0377 USD date February 7, 2025 (source: Banque de France)Sign in to access your portfolio
Globe and Mail
03-03-2025
- Business
- Globe and Mail
Callio Therapeutics Launches with US$187 Million Series A to Advance Multi-Payload Antibody-Drug Conjugate Platform Through Clinical Proof-of-Concept
Frazier Life Sciences launches Callio Therapeutics based on multi-payload antibody-drug conjugate technology and programs exclusively in-licensed from Singapore -based Hummingbird Bioscience Financing led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI Company to advance innovative multi-payload programs designed to maximize therapeutic benefit for cancer patients by overcoming limitations of existing single-payload therapies SEATTLE and SINGAPORE , March 3, 2025 /CNW/ -- Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, today announced its launch with the closing of a $187.0 million Series A financing round. This financing was led by Frazier Life Sciences with significant participation from Jeito Capital alongside other life sciences investors, including Novo Holdings A/S, Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The newly formed company, with headquarters in Seattle and Singapore , intends to use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program. In conjunction with the financing, Callio Therapeutics has entered into an exclusive worldwide license agreement with Hummingbird Bioscience for its multi-payload ADC platform in oncology, and associated intellectual property and pipeline assets, in exchange for equity, potential milestone payments and royalties. "We are delighted to be launching Callio Therapeutics with the support of Frazier Life Sciences and this syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy," said Piers Ingram , PhD, co-founder and Chief Executive Officer of Callio Therapeutics. "This new generation of ADC therapies may meaningfully improve outcomes for patients." Leadership Team The founding Callio Therapeutics management team comprises individuals with extensive experience from leading biotechnology and biopharmaceutical companies including ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, Hummingbird Bioscience and Genentech: Piers Ingram , PhD, Chief Executive Officer Jerome Boyd-Kirkup , PhD, Chief Scientific Officer Naomi Hunder , MD, Chief Medical Officer Angèle Maki, PhD, Chief Business Officer "The multi-payload ADCs being developed at Callio Therapeutics have the potential to address large unmet medical needs by overcoming many of the limitations of existing ADCs," said Adam Simpson , Executive Board Chair of Callio Therapeutics and Venture Partner at Frazier Life Sciences. "With the expertise of the Callio Therapeutics team, together with access to the innovative multi-payload ADC technology, we believe that Callio Therapeutics will be the first company to show the clinical benefit of this exciting new multi-payload ADC approach and is well positioned to transform cancer therapy." About Callio Therapeutics Headquartered in Seattle and Singapore , Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information, please visit and follow Callio Therapeutics on LinkedIn. About Frazier Life Sciences Frazier Life Sciences invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. Frazier Life Sciences manages over $3.9 billion in capital, including Venture Funds focusing on company creation and private companies and the long-only Public Fund focused on small and mid-cap public companies. Since 2005, over 60 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier Life Sciences, have completed IPOs or M&As. The Frazier Life Sciences team consists of over 40 professionals with deep expertise in biopharmaceuticals, primarily located in Palo Alto, Calif. (headquarters), San Diego , Seattle , Boston , New York and London . For more information about Frazier Life Sciences, please visit and follow on LinkedIn. About Hummingbird Bioscience Hummingbird Bioscience is a Singapore -based biotherapeutics company working at the interface of artificial intelligence and human innovation to discover and develop transformative medicines for hard-to-treat diseases. Hummingbird Bioscience's computational and systems biology technologies have generated a pipeline of innovative clinical-stage monoclonal antibodies and antibody-drug conjugates in oncology and autoimmunity. At Hummingbird Bioscience, the commitment to rigorous science, teamwork, and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic. For more information, please visit and follow Hummingbird Bioscience on LinkedIn, X (formerly Twitter), and YouTube.
Associated Press
03-03-2025
- Business
- Associated Press
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients
Jeito Capital announces significant participation in $187 million Series A financing for Callio Therapeutics to advance innovative multi-payload ADC programs designed to maximize therapeutic benefit for cancer patients Callio Therapeutics is a biotechnology company developing multi-payload ADCs with technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience Investment will contribute to achieve clinical proof-of-concept for Callio's HER-2-targeted dual-payload ADC and a second undisclosed ADC program Jeito's investment reinforces its commitment to cutting-edge oncology innovations addressing treatment resistance and improving patient outcomes Paris, March 3rd 2025 – Jeito Capital ('Jeito'), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the $187 million (€180.2 million1) Series A financing round in Callio Therapeutics ('Callio'), a newly launched biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy. Callio Therapeutics was founded by Frazier Life Sciences to develop next-generation multi-payload antibody-drug conjugates (ADCs) based on technology and programs exclusively in-licensed from Singapore-based Hummingbird Bioscience. The company is led by co-founder and CEO Piers Ingram, PhD, alongside a founding management team with deep expertise in ADC development bringing experience from leading biotechnology and biopharmaceutical companies (including Hummingbird Bioscience, ProfoundBio, Silverback Therapeutics, SeaGen, Medarex, and Genentech). The $187 million Series A financing was led by Frazier Life Sciences with significant participation from Jeito alongside an investment syndicate including Novo Holdings A/S Omega Funds, ClavystBio, Platanus, Norwest, Pureos Bioventures, SEEDS Capital and EDBI. The strength of this syndicate underscores the broad confidence in Callio's innovative ADC platform and its potential to reshape cancer therapy. Callio Therapeutics will use the proceeds from the Series A financing to achieve clinical proof-of-concept for its HER2-targeted dual-payload ADC and a second undisclosed ADC program, all designed to maximize therapeutic benefit for cancer patients by overcoming the limitations of single-payload therapies. By enabling the targeted delivery of rational drug combinations to tumor cells, Callio's approach has the potential to significantly enhance efficacy and address resistance mechanisms. Rachel Mears, Partner at Jeito will join Callio's Board of Director as Board member. Through this investment, Jeito reinforces its commitment to supporting transformative oncology innovations that address key resistance mechanisms in cancer treatment. Callio's differentiated multi-payload ADC platform aligns with Jeito's investment thesis of backing high-potential biopharma companies developing next-generation therapies with the potential for global leadership. Dr Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital said: ' We are pleased to support Callio Therapeutics as it advances its differentiated multi-payload ADC platform to address some of the biggest challenges in oncology. As long-standing investors in this therapeutic area, we recognize the quality and potential of Callio's approach to overcome resistance mechanisms and improve outcomes for patients with hard-to-treat cancers. At Jeito, we believe that strategic collaboration and bold innovation are key to accelerating the next generation of targeted therapies, and we look forward to working alongside the Callio team to bring these advances to patients in need. ' Rachel Mears, Parner at Jeito Capital added: ' Callio is a highly innovative company that benefits from an experienced management team and deep expertise in oncology, where new therapies remain highly needed for those suffering from various forms of cancer. We look forward to collaborating with Callio's team through our collective knowledge and expertise in both ADC and oncology with the ambition to go faster to patients with high unmet needs. ' Piers Ingram, PhD, co-founder and Chief Executive Officer of Callio Therapeutics concluded: ' We are delighted to be launching Callio Therapeutics with this very strong syndicate of investors. Multi-payload ADCs have the potential to enable the targeted delivery of rational drug combinations to cancer cells, and may provide significantly enhanced efficacy. This new generation of ADC therapies may meaningfully improve outcomes for patients.' About Jeito Capital Jeito Capital is a global leading Private Equity fund with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients' access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States. For more information, please visit or follow us on LinkedIn or X. About Callio Therapeutics Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics' lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience. For more information , please visit and follow Callio Therapeutics on LinkedIn. Contacts: Jeito Capital Rafaèle Tordjman, Founder & CEO Jessica Fadel, EA Tel: +33 6 33 44 25 47 Maior Stéphanie Elbaz – Tel: +33 6 46 05 08 07 ICR Healthcare Mary-Jane Elliott / Davide Salvi / Kris Lam
